Menu
No results found.
Weekly Share Price & Valuation Overview
Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Debt-to-equity >2 — elevated leverage may constrain flexibility.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- USD 1.68B
- Enterprise Value Operating value: market cap + total debt − cash.
- USD 1.76B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- USD 333.86M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- USD 113.49M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- USD -120.54M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- USD 3.95
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -2.02
- Shares Outstanding
- 89.14M
- Float Shares
- 79.29M
- Implied Shares Outstanding
- 89.14M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-11.05%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
-36.10%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
33.99%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-50.64%
- ROA Return on assets: net income ÷ total assets.
-
-19.28%
- ROE Return on equity: net income ÷ shareholder equity.
-
-7.06%
- Revenue Growth Year-over-year revenue growth.
-
1.11%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.90
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 12.20
- Total Cash Cash and equivalents.
- USD 319.54M
- Total Debt Short + long-term interest-bearing debt.
- USD 399.57M
- Net Debt Total debt − cash (negative = net cash).
- USD 80.04M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- -3.31
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- USD -115.44M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- USD -81.79M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-34.58%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-24.50%
- Cash Conversion (OpCF/EBITDA)
- 0.96
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.